Dual duty

Amgen Inc.'s collaboration with Xencor Inc. will give it the chance to test its BiTE technology head to head against Xencor's bispecific platform while learning how to make new agents alongside its partner.

The companies partnered last week to develop six bispecific antibodies for cancer and inflammatory indications, including Xencor's preclinical program targeting the CD38 antigen and CD3. For the other five, Amgen will specify the targets and antibodies that Xencor will use to produce bispecific constructs...